Date: 28-Aug-2019

Novo Nordisk has announced Fiasp approved for children in Europe

Novo Nordisk has announced that the European Commission has granted an extension of the indication for its fast-acting insulin aspart, Fiasp. The extension is for the treatment of diabetes in adolescents and children (aged one year and above), complementing the previous indication, which covered adults only.